Sai Life Sciences has delivered a robust financial performance for the year ended 31 March 2026, reporting a 29% YoY revenue increase to ₹2,192 crore. The company saw significant margin expansion, with EBITDA rising 56% to ₹661 crore and PAT growing by 109% to ₹355 crore. Driven by strong execution in its CRDMO business, the company is now scaling investments for future growth with a planned ₹1,100–1,300 crore Capex for FY27.
Financial Performance Highlights
The company achieved a strong fiscal year 2026, with consolidated revenue reaching ₹2,192 crore, a 29% increase over the previous year. Profitability saw a substantial boost, with EBITDA growing 56% to ₹661 crore and Profit After Tax (PAT) surging 109% to ₹355 crore. EBITDA margins expanded by 508 basis points, reaching 30%, attributed to improved operational leverage across employee and material costs.
Segmental Growth and Market Reach
Sai Life Sciences’ core divisions showed consistent momentum. The CDMO segment recorded revenues of ₹1,417 crore, reflecting a 33% growth, while the CRO segment posted revenues of ₹775 crore, a 24% rise. The company continues to serve a global client base, with 19 of the top 25 global pharma companies as customers and an average relationship tenure exceeding 11 years.
Strategic Investments and Future Outlook
To capitalize on increasing global demand for integrated R&D and manufacturing, the company has announced a front-loaded investment cycle. For FY27, the board has approved a substantial Capex allocation of ₹1,100–1,300 crore. Approximately 75% of this spend is earmarked for capacity expansion, with the remainder dedicated to AI, technology, and new capabilities like peptides and ADCs. Management remains confident in achieving a 15-20% revenue CAGR over the next 3-5 years, while maintaining robust EBITDA margins of 28-30%.
Sustainability and Digital Leadership
The company continues to advance its ESG commitments, notably at the Bidar manufacturing site, which has become the first Indian CRDMO facility to operate on 100% renewable energy. Simultaneously, the company is deepening its digitalization and AI integration, with 85% of R&D and manufacturing processes now digitized to enhance operational speed and decision-making.
Source: BSE
